Montag A & Associates Inc. Purchases 11,787 Shares of Boston Scientific Co. (NYSE:BSX)

Montag A & Associates Inc. lifted its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 421.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,587 shares of the medical equipment provider's stock after purchasing an additional 11,787 shares during the period. Montag A & Associates Inc.'s holdings in Boston Scientific were worth $843,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. increased its stake in Boston Scientific by 25.9% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 42,606 shares of the medical equipment provider's stock worth $2,250,000 after acquiring an additional 8,766 shares during the period. Park Avenue Securities LLC bought a new position in Boston Scientific during the 3rd quarter worth $562,000. TD Asset Management Inc increased its stake in Boston Scientific by 27.8% during the 3rd quarter. TD Asset Management Inc now owns 1,460,367 shares of the medical equipment provider's stock worth $77,107,000 after acquiring an additional 318,058 shares during the period. State of Michigan Retirement System increased its stake in Boston Scientific by 1.5% during the 3rd quarter. State of Michigan Retirement System now owns 401,408 shares of the medical equipment provider's stock worth $21,194,000 after acquiring an additional 6,100 shares during the period. Finally, Carmel Capital Partners LLC increased its stake in Boston Scientific by 2,252.7% during the 3rd quarter. Carmel Capital Partners LLC now owns 1,294 shares of the medical equipment provider's stock worth $68,000 after acquiring an additional 1,239 shares during the period. Institutional investors own 89.07% of the company's stock.

Insiders Place Their Bets

In other Boston Scientific news, Director Charles J. Dockendorff sold 3,946 shares of the business's stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total transaction of $286,874.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Charles J. Dockendorff sold 3,946 shares of the business's stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total value of $286,874.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 9,818 shares of the business's stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $73.29, for a total value of $719,561.22. Following the completion of the transaction, the director now owns 41,374 shares in the company, valued at approximately $3,032,300.46. The disclosure for this sale can be found here. In the last ninety days, insiders sold 82,330 shares of company stock valued at $5,682,434. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Down 0.6 %

BSX traded down $0.41 during midday trading on Friday, reaching $73.69. 3,788,684 shares of the company were exchanged, compared to its average volume of 6,559,960. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The company's fifty day moving average price is $68.95 and its 200 day moving average price is $61.90. The company has a market cap of $108.11 billion, a price-to-earnings ratio of 62.03, a price-to-earnings-growth ratio of 2.51 and a beta of 0.77. Boston Scientific Co. has a one year low of $48.35 and a one year high of $74.39.

Analyst Ratings Changes

A number of equities analysts have commented on BSX shares. Royal Bank of Canada raised their price objective on Boston Scientific from $78.00 to $82.00 and gave the stock an "outperform" rating in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft raised their target price on Boston Scientific from $63.00 to $73.00 and gave the company a "hold" rating in a report on Thursday, April 25th. Wells Fargo & Company raised their target price on Boston Scientific from $72.00 to $82.00 and gave the company an "overweight" rating in a report on Thursday, April 25th. TD Cowen lifted their target price on Boston Scientific from $65.00 to $77.00 and gave the stock an "outperform" rating in a report on Thursday, March 7th. Finally, Mizuho lifted their target price on Boston Scientific from $80.00 to $85.00 and gave the stock a "buy" rating in a report on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $75.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.